[1]
|
Thurston, R.D., et al. (2010) Tumor Necrosis Factor and Interferon-Gamma Down-Regulate Klotho in Mice with Colitis. Gastroenterology, 138, 1384-1394.e1-2. https://doi.org/10.1053/j.gastro.2009.12.002
|
[2]
|
Hernández-Tejero, M., et al. (2017) Prevalence, Risk Factors and Response to Treatment of Extra-Intestinal Manifestations in Patients with In-flammatory Bowel Disease. Revista Espanola De Enfermedades Digestivas, 109, 627-633.
https://doi.org/10.17235/reed.2017.4845/2017
|
[3]
|
Jansen, F.M., et al. (2020) Clinical Management of the Most Common Extra-Intestinal Manifestations in Patients with Inflammatory Bowel Disease Focused on the Joints, Skin and Eyes. United European Gastroenterology Journal, 8, 1031-1044. https://doi.org/10.1177/2050640620958902
|
[4]
|
Pouillon, L., et al. (2017) Management of Patients with Inflam-matory Bowel Disease and Spondyloarthritis. Expert Review of Clinical Pharmacology, 10, 1363-1374. https://doi.org/10.1080/17512433.2017.1377609
|
[5]
|
Greuter, T., Navarini, A. and Vavricka, S.R. (2017) Skin Manifestations of Inflammatory Bowel Disease. Clinical Reviews in Allergy & Immunology, 53, 413-427. https://doi.org/10.1007/s12016-017-8617-4
|
[6]
|
Makredes, M., et al. (2009) The Burden of Autoimmune Disease: A Comparison of Prevalence Ratios in Patients with Psoriatic Arthritis and Psoriasis. Journal of the American Academy of Dermatology, 61, 405-410.
https://doi.org/10.1016/j.jaad.2009.02.015
|
[7]
|
World Health Organization (2016) Global Report on Psoriasis. World Health Organization, Geneva.
|
[8]
|
Alzeer, F., AlOtair, H. and Aleisa, A. (2022) Epidemiology and Cutaneous Manifestations of Psoriasis in Saudi Arabia: A Narrative Review. Clinical, Cosmetic and Investigational Dermatology, 15, 347-355.
https://doi.org/10.2147/CCID.S352654
|
[9]
|
Campanati, A., et al. (2021) Psoriasis as an Immune-Mediated and In-flammatory Systemic Disease: From Pathophysiology to Novel Therapeutic Approaches. Biomedicines, 9, Article No. 1511.
https://doi.org/10.3390/biomedicines9111511
|
[10]
|
De Francesco, M.A. and Caruso, A. (2022) The Gut Microbi-ome in Psoriasis and Crohn’s Disease: Is Its Perturbation a Common Denominator for Their Pathogenesis? Vaccines (Basel), 10, Article No. 244.
https://doi.org/10.3390/vaccines10020244
|
[11]
|
Hedin, C.R.H., et al. (2021) Inflammatory Bowel Disease and Pso-riasis: Modernizing the Multidisciplinary Approach. Journal of Internal Medicine, 290, 257-278. https://doi.org/10.1111/joim.13282
|
[12]
|
Myers, B., et al. (2019) The Gut Microbiome in Psoriasis and Psoriatic Arthritis. Best Practice & Research: Clinical Rheumatology, 33, Article ID: 101494. https://doi.org/10.1016/j.berh.2020.101494
|
[13]
|
Alinaghi, F., et al. (2020) Global Prevalence and Bidirectional Association between Psoriasis and Inflammatory Bowel Disease—A Systematic Review and Meta-Analysis. Journal of Crohn’s and Colitis, 14, 351-360.
https://doi.org/10.1093/ecco-jcc/jjz152
|
[14]
|
Wright, S., et al. (2020) Real-World Risk of New-Onset Inflammatory Bowel Disease among Patients with Psoriasis Exposed to Interleukin 17 Inhibitors. Journal of the American Academy of Dermatology, 83, 382-387.
https://doi.org/10.1016/j.jaad.2020.04.010
|
[15]
|
Yousaf, A., et al. (2021) Association between Psoriasis, Psoriatic Arthritis and Gastrointestinal Disease: An Exploratory Nationwide Inpatient Sample Analysis. Wiener Klinische Woch-enschrift, 133, 586-593.
https://doi.org/10.1007/s00508-020-01740-8
|
[16]
|
King, D., et al. (2021) The Risk of Later Diagnosis of Inflam-matory Bowel Disease in Patients with Dermatological Disorders Associated with Inflammatory Bowel Disease. In-flammatory Bowel Diseases, 27, 1731-1739.
https://doi.org/10.1093/ibd/izaa344
|
[17]
|
Lee, J.Y., et al. (2019) Psoriasis Increases the Risk of Concurrent Inflam-matory Bowel Disease: A Population-Based Nationwide Study in Korea. Indian Journal of Dermatology, Venereology and Leprology, 85, 145-152.
https://doi.org/10.4103/ijdvl.IJDVL_875_17
|
[18]
|
Card, T.R., Langan, S.M. and Chu, T.P. (2016) Ex-tra-Gastrointestinal Manifestations of Inflammatory Bowel Disease May Be Less Common than Previously Reported. Digestive Diseases and Sciences, 61, 2619-2626.
https://doi.org/10.1007/s10620-016-4195-1
|
[19]
|
Kim, M., et al. (2017) Inflammatory Bowel Disease Is Associated with an Increased Risk of Inflammatory Skin Diseases: A Population-Based Cross-Sectional Study. Journal of the American Academy of Dermatology, 76, 40-48.
https://doi.org/10.1016/j.jaad.2016.08.022
|
[20]
|
Koumaki, D., et al. (2021) Mucocutaneous Manifestations in Pa-tients with Inflammatory Bowel Disease: A Decade Study from a Greek Cohort. European Journal of Gastroenterology & Hepatology, 33, 1387-1393.
https://doi.org/10.1097/MEG.0000000000002053
|
[21]
|
Halling, M.L., et al. (2017) Patients with Inflammatory Bowel Disease Have Increased Risk of Autoimmune and Inflammatory Diseases. World Journal of Gastroenterology, 23, 6137-6146. https://doi.org/10.3748/wjg.v23.i33.6137
|
[22]
|
Jo, U.H., et al. (2021) Various Skin Manifestations Re-lated to Inflammatory Bowel Disease: A Nationwide Cross-Sectional Study on the Korean Population. The Journal of Dermatology, 48, 431-438. https://doi.org/10.1111/1346-8138.15676
|
[23]
|
Karmiris, K., et al. (2016) Prevalence and Characteristics of Extra-Intestinal Manifestations in a Large Cohort of Greek Patients with Inflammatory Bowel Dis-ease. Journal of Crohn’s and Colitis, 10, 429-436.
https://doi.org/10.1093/ecco-jcc/jjv232
|
[24]
|
Yates, V.M., Watkinson, G. and Kelman, A. (1982) Further Evidence for an Association between Psoriasis, Crohn’s Disease and Ulcerative Colitis. British Journal of Dermatology, 106, 323-330.
https://doi.org/10.1111/j.1365-2133.1982.tb01731.x
|
[25]
|
Vavricka, S.R., et al. (2015) Chronological Order of Ap-pearance of Extraintestinal Manifestations Relative to the Time of IBD Diagnosis in the Swiss Inflammatory Bowel Dis-ease Cohort. Inflammatory Bowel Diseases, 21, 1794-1800.
https://doi.org/10.1097/MIB.0000000000000429
|
[26]
|
Lakatos, L., et al. (2003) Association of Extraintestinal Manifestations of Inflammatory Bowel Disease in a Province of Western Hungary with Disease Phenotype: Results of a 25-Year Follow-Up Study. World Journal of Gastroenterology, 9, 2300-2307. https://doi.org/10.3748/wjg.v9.i10.2300
|
[27]
|
Yüksel, I., et al. (2009) Mucocutaneous Manifestations in Inflamma-tory Bowel Disease. Inflammatory Bowel Diseases, 15, 546-550. https://doi.org/10.1002/ibd.20807
|
[28]
|
Napolitano, M., et al. (2019) Psoriasis Features in Patients with Inflamma-tory Bowel Disease. Open Access Macedonian Journal of Medical Sciences, 7, 1001-1003. https://doi.org/10.3889/oamjms.2019.161
|
[29]
|
Vide, J., et al. (2018) Cutaneous Morbidity among Inflammatory Bowel Disease Patients: A Cohort Study. Journal of Crohn’s and Colitis, 12, 442-451. https://doi.org/10.1093/ecco-jcc/jjx178
|
[30]
|
Bernstein, C.N., Wajda, A. and Blanchard, J.F. (2005) The Clustering of Other Chronic Inflammatory Diseases in Inflammatory Bowel Disease: A Population-Based Study. Gastroenterology, 129, 827-836.
https://doi.org/10.1053/j.gastro.2005.06.021
|
[31]
|
Hammer, B., Ashurst, P. and Naish, J. (1968) Diseases Associ-ated with Ulcerative Colitis and Crohn’s Disease. Gut, 9, 17-21. https://doi.org/10.1136/gut.9.1.17
|
[32]
|
Weng, X., et al. (2007) Clustering of Inflammatory Bowel Disease with Immune Mediated Diseases among Members of a Northern California-Managed Care Organization. The American Journal of Gastroenterology, 102, 1429-1435.
https://doi.org/10.1111/j.1572-0241.2007.01215.x
|
[33]
|
Bardella, M.T., et al. (2009) Autoimmune Disorders In Pa-tients Affected by Celiac Sprue and Inflammatory Bowel Disease. Annals of Medicine, 41, 139-143. https://doi.org/10.1080/07853890802378817
|
[34]
|
Ciccacci, C., et al. (2013) TRAF3IP2 Gene Is Associated with Cutaneous Extraintestinal Manifestations in Inflammatory Bowel Disease. Journal of Crohn’s and Colitis, 7, 44-52. https://doi.org/10.1016/j.crohns.2012.02.020
|
[35]
|
Singh, B., et al. (2015) Extraintestinal Manifestations of Inflam-matory Bowel Disease and Intestinal Tuberculosis: Frequency and Relation with Disease Phenotype. Indian Journal of Gastroenterology, 34, 43-50.
https://doi.org/10.1007/s12664-015-0538-7
|
[36]
|
Ghersin, I., et al. (2020) Comorbidities in Adolescents with In-flammatory Bowel Disease: Findings from a Population-Based Cohort Study. Pediatric Research, 87, 1256-1262. https://doi.org/10.1038/s41390-019-0702-3
|
[37]
|
Bar Yehuda, S., et al. (2019) The Association of Inflammatory Bowel Diseases with Autoimmune Disorders: A Report from the epi-IIRN. Journal of Crohn’s and Colitis, 13, 324-329. https://doi.org/10.1093/ecco-jcc/jjy166
|
[38]
|
Edigin, E., et al. (2020) Coexisting Psoriasis Is Associated with an In-creased Risk of Hospitalization for Patients with Inflammatory Bowel Disease: An Analysis of the National Inpatient Sample Database. Journal of Investigative Medicine, 69, 857-862. https://doi.org/10.1136/jim-2020-001689
|
[39]
|
Lolli, E., et al. (2015) Psoriasis Phenotype in Inflammatory Bowel Disease: A Case-Control Prospective Study. Journal of Crohn’s and Colitis, 9, 699-707. https://doi.org/10.1093/ecco-jcc/jjv068
|
[40]
|
Sridhar, S., et al. (2018) Dermatological Manifestations in Pediatric Pa-tients with Inflammatory Bowel Diseases on Anti-TNF Therapy. Inflammatory Bowel Diseases, 24, 2086-2092. https://doi.org/10.1093/ibd/izy112
|
[41]
|
George, L.A., et al. (2015) Psoriasiform Skin Lesions Are Caused by An-ti-TNF Agents Used for the Treatment of Inflammatory Bowel Disease. Digestive Diseases and Sciences, 60, 3424-3430.
https://doi.org/10.1007/s10620-015-3763-0
|
[42]
|
Peer, F.C., et al. (2017) Paradoxical Psoriasiform Reactions of Anti-Tumour Necrosis Factor Therapy in Inflammatory Bowel Disease Patients. Internal Medicine Journal, 47, 1445-1448. https://doi.org/10.1111/imj.13637
|
[43]
|
Fréling, E., et al. (2015) Cumulative Incidence of, Risk Factors for, and Outcome of Dermatological Complications of Anti-TNF Therapy in Inflammatory Bowel Disease: A 14-Year Experience. The American Journal of Gastroenterology, 110, 1186-1196. https://doi.org/10.1038/ajg.2015.205
|
[44]
|
Pugliese, D., et al. (2015) Paradoxical Psoriasis in a Large Cohort of Pa-tients with Inflammatory Bowel Disease Receiving Treatment with Anti-TNF Alpha: 5-Year Follow-Up Study. Alimen-tary Pharmacology & Therapeutics, 42, 880-888. https://doi.org/10.1111/apt.13352
|
[45]
|
Weizman, A.V., et al. (2018) Stricturing and Fistulizing Crohn’s Disease Is Associated with Anti-Tumor Necrosis Factor-Induced Psoriasis in Patients with Inflammatory Bowel Disease. Digestive Diseases and Sciences, 63, 2430-2438.
https://doi.org/10.1007/s10620-018-5096-2
|
[46]
|
Buckley, L.H., et al. (2021) Psoriasis Associated with Tumor Ne-crosis Factor Inhibitors in Children with Inflammatory Diseases. Arthritis Care & Research (Hoboken), 73, 215-220. https://doi.org/10.1002/acr.24100
|
[47]
|
Courbette, O., et al. (2019) Infliximab Paradoxical Psoriasis in a Cohort of Children with Inflammatory Bowel Disease. Journal of Pediatric Gastroenterology and Nutrition, 69, 189-193. https://doi.org/10.1097/MPG.0000000000002349
|
[48]
|
Andrade, P., et al. (2018) Anti-Tumor Necrosis Fac-tor-α-Induced Dermatological Complications in a Large Cohort of Inflammatory Bowel Disease Patients. Digestive Dis-eases and Sciences, 63, 746-754.
https://doi.org/10.1007/s10620-018-4921-y
|
[49]
|
Tillack, C., et al. (2014) Anti-TNF Antibody-Induced Psori-asiform Skin Lesions in Patients with Inflammatory Bowel Disease Are Characterised by Interferon-γ-Expressing Th1 Cells and IL-17A/IL-22-Expressing Th17 Cells and Respond to Anti-IL-12/IL-23 Antibody Treatment. Gut, 63, 567-577. https://doi.org/10.1136/gutjnl-2012-302853
|
[50]
|
Guerra, I., et al. (2016) Incidence, Clinical Characteristics, and Management of Psoriasis Induced by Anti-TNF Therapy in Patients with Inflammatory Bowel Disease: A Nationwide Cohort Study. Inflammatory Bowel Diseases, 22, 894-901. https://doi.org/10.1097/MIB.0000000000000757
|
[51]
|
Protic, M., et al. (2016) Development of Psoriasis in IBD Patients under TNF-Antagonist Therapy Is Associated neither with Anti-TNF-Antagonist Antibodies nor Trough Levels. Scandinavian Journal of Gastroenterology, 51, 1482-1488.
https://doi.org/10.1080/00365521.2016.1218541
|
[52]
|
Fedor, I., Zold, E. and Barta, Z. (2021) Temporal Relation-ship of Extraintestinal Manifestations in Inflammatory Bowel Disease. Journal of Clinical Medicine, 10, Article No. 5984. https://doi.org/10.3390/jcm10245984
|
[53]
|
Park, S.K., et al. (2021) Extraintestinal Manifestation of Inflammatory Bowel Disease in Asian Patients: A Multinational Study. Digestive and Liver Disease, 53, 196-201. https://doi.org/10.1016/j.dld.2020.06.046
|
[54]
|
Al-Janabi, A. and Yiu, Z.Z.N. (2022) Biologics in Psoriasis: Up-dated Perspectives on Long-Term Safety and Risk Management. Psoriasis (Auckl), 12, 1-14. https://doi.org/10.2147/PTT.S328575
|
[55]
|
Baeten, D., et al. (2003) Systematic Safety Follow Up in a Cohort of 107 Patients with Spondyloarthropathy Treated with Infliximab: A New Perspective on the Role of Host Defence in the Pathogenesis of the Disease? Annals of Rheumatic Diseases, 62, 829-834. https://doi.org/10.1136/ard.62.9.829
|
[56]
|
Xie, W., et al. (2022) Incidence of and Risk Factors for Paradoxical Pso-riasis or Psoriasiform Lesions in Inflammatory Bowel Disease Patients Receiving Anti-TNF Therapy: Systematic Review with Meta-Analysis. Frontiers in Immunology, 13, Article ID: 847160. https://doi.org/10.3389/fimmu.2022.847160
|
[57]
|
Ott, C., et al. (2014) Smoking Increases the Risk of Extraintesti-nal Manifestations in Crohn’s Disease. World Journal of Gastroenterology, 20, 12269-12276. https://doi.org/10.3748/wjg.v20.i34.12269
|
[58]
|
Yang, M., et al. (2021) The Incidence of Psoriasis among Smokers and/or Former Smokers Inflammatory Bowel Diseases Patients Treated with Tumor Necrosis Factor Antagonist: A Sys-tematic Review and Meta-Analysis. Medicine (Baltimore), 100, e27510. https://doi.org/10.1097/MD.0000000000027510
|
[59]
|
Nguyen, U.D.T., et al. (2018) Smoking Paradox in the De-velopment of Psoriatic Arthritis among Patients with Psoriasis: A Population-Based Study. Annals of Rheumatic Diseas-es, 77, 119-123.
https://doi.org/10.1136/annrheumdis-2017-211625
|
[60]
|
Mahid, S.S., et al. (2006) Smoking and Inflammatory Bowel Disease: A Meta-Analysis. Mayo Clinic Proceedings, 81, 1462-1471. https://doi.org/10.4065/81.11.1462
|
[61]
|
Prtina, A., et al. (2021) The Effect of Three-Month Vitamin D Supple-mentation on the Levels of Homocysteine Metabolism Markers and Inflammatory Cytokines in Sera of Psoriatic Patients. Biomolecules, 11, Article No. 1865.
https://doi.org/10.3390/biom11121865
|
[62]
|
Wierzbicka, J.M., et al. (2021) The Effects of Vitamin D on the Ex-pression of IL-33 and Its Receptor ST2 in Skin Cells; Potential Implication for Psoriasis. International Journal of Molec-ular Sciences, 22, Article No. 12907.
https://doi.org/10.3390/ijms222312907
|
[63]
|
Chandra, R., Roesyanto-Mahadi, I.D. and Yosi, A. (2020) Pilot Study: Immunohistochemistry Expressions of Vitamin D Receptor Associated with Severity of Disease in Psoriasis Patients. International Journal of Dermatology, 59, 1092-1097. https://doi.org/10.1111/ijd.15018
|
[64]
|
Fu, H., et al. (2021) Relationship between Vitamin D Level and Mortality in Adults with Psoriasis: A Retrospective Cohort Study of NHANES Data. Clinical Therapeutics, 43, e33-e38. https://doi.org/10.1016/j.clinthera.2020.11.016
|
[65]
|
Murdaca, G., et al. (2019) Emerging Role of Vitamin D in Autoimmune Diseases: An Update on Evidence and Therapeutic Impli-cations. Autoimmunity Reviews, 18, Article ID: 102350. https://doi.org/10.1016/j.autrev.2019.102350
|
[66]
|
Schäffler, H., et al. (2018) Clinical Factors Are Associated with Vitamin D Levels in IBD Patients: A Retrospective Analysis. Journal of Digestive Diseases, 19, 24-32. https://doi.org/10.1111/1751-2980.12565
|
[67]
|
Abd-El-Aziz, M.A., et al. (2022) Simple Clinical Screening Underestimates Malnutrition in Surgical Patients with Inflammatory Bowel Dis-ease—An ACS NSQIP Analysis. Nutrients, 14, Article No. 932.
https://doi.org/10.3390/nu14050932
|
[68]
|
Taleban, S., et al. (2016) Ocular Manifestations in Inflammatory Bowel Disease Are Associated with Other Extra-Intestinal Manifestations, Gender, and Genes Implicated in Other Im-mune-Related Traits. Journal of Crohn’s and Colitis, 10, 43-49. https://doi.org/10.1093/ecco-jcc/jjv178
|
[69]
|
Köse, B., Uzlu, D. and Erdöl, H. (2022) Psoriasis and Uveitis. International Ophthalmology, 42, 2303-2310.
https://doi.org/10.1007/s10792-022-02225-5
|
[70]
|
Wu, J.J., et al. (2022) Psoriasis and Metabolic Syndrome: Im-plications for the Management and Treatment of Psoriasis. The Journal of the European Academy of Dermatology and Venereology, 36, 797-806.
https://doi.org/10.1111/jdv.18044
|